全球水痘病毒疫苗市場規模（依疫苗、應用、供應商、區域覆蓋）預測（至 2025 年）

水痘疫苗的市場規模及預測

2024 年水痘病毒疫苗市場規模為 35.3652 億美元，預計到 2032 年將達到 54.4344 億美元，預測期內（2026-2032 年）的複合年成長率為 6.11%。

推動全球水痘病毒疫苗市場的因素

水痘病毒疫苗市場的促進因素可能受到多種因素的影響。這些因素包括：

• 帶狀皰疹和水痘發病率不斷上升。全球帶狀皰疹和水痘感染率不斷上升，推動了對水痘病毒疫苗的需求。水痘傳染性極強，尤其是在青少年中，曾經患過水痘的人也可能感染帶狀皰疹，因此接種疫苗對於預防這兩種疾病至關重要。
• 政府免疫計劃：水痘病毒疫苗接種率在很大程度上受到政府主導的免疫計劃的影響，尤其是在已開發國家和開發中國家。兒童、青少年和成人的常規水痘疫苗接種通常被納入國家免疫方案，增加了疫苗接種率和市場需求。
• 衛生當局的指南和建議：世界衛生組織 (WHO)、美國疾病管制與預防中心 (CDC) 以及其他國家衛生當局已發布指南和建議，支持使用水痘病毒疫苗作為預防水痘和帶狀皰疹的措施。醫療保健提供者對這些建議的遵守有助於市場成長。
• 由於疫苗技術的進步，包括重組疫苗和減毒活病毒疫苗的研發，水痘病毒疫苗如今更安全、更有效、更方便。近期製劑性能的提升正推動著市場的成長與滲透。
• 合併疫苗：患者和醫護人員發現，合併疫苗可以預防多種可透過疫苗預防的疾病，例如水痘、麻疹、流行性腮腺炎和德國德國麻疹，更便捷，也提高了依從性。水痘病毒疫苗產業的成長部分得益於聯合疫苗。
• 增強對疫苗接種益處的認知：增強對疫苗接種益處的認知，例如避免水痘相關併發症，例如腦炎、肺炎以及隨後的細菌感染，將有助於提高個人和家長的疫苗接種率。公共衛生宣傳活動和教育計畫支持將疫苗接種作為一種預防措施。
• 提高免疫覆蓋率：市場擴張的動力源自於提高免疫覆蓋率的努力，尤其是在貧困人群和疾病高發生地區。水痘病毒疫苗接種已變得更加普及，透過有針對性的疫苗宣傳活動、學校疫苗接種計劃和推廣活動，減少了疾病的傳播。
• 疫苗接種的經濟效益：水痘和帶狀皰疹疫苗接種可降低疾病治療、住院和疾病導致的生產力損失等醫療成本，進而帶來經濟效益。衛生經濟學研究表明，水痘病毒疫苗接種費用低廉，推動了市場擴張。
• 醫療保健支出不斷成長：受人口成長、人口老化以及醫療基礎設施建設等因素的影響，人們在疫苗接種等預防性醫療保健措施上的投資能力不斷增強。醫療保健投資的增加推動了水痘病毒疫苗市場的成長。
• 全球努力預防疫苗可預防疾病：全球努力預防和控制水痘等疫苗可預防疾病，將對市場成長產生正面影響。各國政府、國際組織和疫苗製造商正在共同努力，使高風險地區更容易獲得水痘疫苗接種。

限制全球水痘病毒疫苗市場的因素

有幾個因素可能會對水痘病毒疫苗市場造成限制或挑戰。這些因素包括：

• 疫苗接種覆蓋率有限：目前已有水痘病毒疫苗接種，但不同族群和地區的疫苗接種率有差異。接種意願、錯誤訊息以及對疫苗益處缺乏了解等因素可能會影響疫苗接種率和覆蓋率。
• 監管挑戰：獲得水痘病毒疫苗的監管批准可能既困難又耗時。包括臨床試驗、上市後監測以及安全性和有效性評估在內的監管要求可能會增加疫苗研發和商業化所需的成本和時間。
• 疫苗分發和供應挑戰：確保充足且穩定的疫苗供應以滿足水痘病毒疫苗的需求可能頗具挑戰性。生產延誤、供應鏈中斷以及分發問題都可能影響疫苗供應，尤其是在醫療資源和基礎設施不足的地區。
• 生產成本高：生產水痘病毒疫苗需要專門的生產技術和嚴格的品管方法。高昂的生產成本（包括設施、設備和原料的投資）可能會影響疫苗的價格和供應，尤其是在中低收入國家。
• 低溫運輸需求：為了維持疫苗的功效和效力，水痘疫苗與許多其他疫苗一樣，必須在整個低溫運輸中嚴格控制溫度。低溫運輸物流，包括搬運、儲存和運輸，可能會給疫苗製造商和經銷商帶來物流挑戰並增加成本。
• 來自替代疫苗的競爭：預防水痘的疫苗接種計劃和替代疫苗對水痘病毒疫苗構成了威脅。某些國家決定使用可預防多種疾病的聯合疫苗，可能會影響水痘疫苗市場的需求。
• 疾病流行病學和人口趨勢：水痘是一種流行病學可能隨時間和地區變化的疾病，其流行病學受人口密度、疫苗接種率和人口結構變化等多種因素的影響。水痘流行病學的變化和盛行率的下降可能會影響市場動態和疫苗接種需求。
• 疫苗安全問題：水痘病毒疫苗相關的不利事件和安全問題可能會損害大眾對疫苗宣傳活動的信心。解決安全問題、實施嚴格的上市後監測以及對醫療保健提供者和公眾保持開放和誠實的態度，對於維持疫苗接種的接受度和普及度至關重要。
• 醫療預算限制：由於醫療目標相互衝突以及預算限制，政府對水痘疫苗接種計畫的資金籌措和投入可能有限。財政資源不足可能阻礙弱勢族群接種疫苗，阻礙提高疫苗接種覆蓋率的努力。
• 大流行和感染疾病爆發是全球衛生緊急事件的例子，它們可能會擾亂常規疫苗接種計劃，並挪用水痘疫苗接種工作的資金。公共衛生緊急事件也可能導致疫苗接種需求增加，給醫療保健系統和疫苗供應網路帶來額外壓力。

目錄

第1章全球水痘病毒疫苗市場簡介

• 市場概覽
• 研究範圍
• 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

• 資料探勘
• 驗證
• 第一手資料
• 資料來源列表

第4章全球水痘疫苗市場展望

• 概述
• 市場動態
  • 驅動程式
  • 限制因素
  • 機會
• 波特五力模型
• 價值鏈分析

5. 全球水痘病毒疫苗市場（依疫苗類型）

• 概述
• 單價水痘疫苗
• 水痘聯合疫苗

6. 全球水痘病毒疫苗市場（依應用）

• 概述
• 水痘疫苗接種
• 帶狀皰疹疫苗接種
• 腮腺炎
• 麻疹
• 德國麻疹
• 水痘（MMRV）疫苗接種

7. 全球水痘病毒疫苗市場（依供應商）

• 概述
• 民眾
• 私人的

8. 全球水痘病毒疫苗市場（按地區）

• 概述
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 世界其他地區
  • 拉丁美洲
  • 中東和非洲

9. 全球水痘病毒疫苗市場競爭格局

• 概述
• 各公司市場排名
• 主要發展策略

第10章 公司簡介

• Bio-Med Pvt. Limited
• Changchun BCHT Biotechnology Co. Ltd.
• Emcure Pharmaceuticals Limited
• GlaxoSmithKline plc
• Green Cross Holdings（GC Pharma）
• Merck & Co. Inc.
• Mitsubishi Chemical Holdings Corporation
• Novo Medi Sciences Pvt. Ltd.
• Sanofi
• Takeda Pharmaceutical Company Limited

第11章 附錄

• 相關調查

Varicella Virus Vaccine Market Size And Forecast

Varicella Virus Vaccine Market size was valued at USD 3536.52 Million in 2024 and is projected to reach USD 5443.44 Million by 2032, growing at a CAGR of 6.11% during the forecast period 2026-2032.

Global Varicella Virus Vaccine Market Drivers

The market drivers for the Varicella Virus Vaccine Market can be influenced by various factors. These may include:

• Growing Rates of Herpes Zoster and Varicella The need for varicella virus vaccines is driven by the rising global prevalence of herpes zoster and varicella infections. Because varicella is very communicable, especially in youngsters, and because those who have had varicella before might have herpes zoster, immunization is necessary to prevent both illnesses.
• Government Immunization Programs: The uptake of varicella virus vaccinations is largely influenced by government-led immunization programs, especially in industrialized and developing nations. Routine varicella vaccination for children, adolescents, and adults is frequently included in national immunization regimens, which boosts vaccine uptake and market demand.
• Health Authorities' Guidelines and Recommendations: The World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and other national health agencies have released guidelines and recommendations that support the use of varicella virus vaccines as a preventative measure against varicella and herpes zoster. Healthcare providers contribute to market growth by adhering to these recommendations.
• Varicella virus vaccines are now safer, more effective, and more convenient because to ongoing developments in vaccine technology, such as the creation of recombinant and live attenuated vaccines. Improved properties of more recent formulations boost market growth and uptake.
• Combination Vaccines: Patients and healthcare professionals find it more convenient and compliant when there are combination vaccines available that offer protection against several diseases, such as varicella, measles, mumps, rubella, and other diseases that can be prevented by vaccination. The varicella virus vaccine industry is growing in part because to combination vaccinations.
• Increasing Knowledge of the Benefits of Vaccination: Raising knowledge of the advantages of vaccination, such as its ability to avoid complications connected to varicella, such as encephalitis, pneumonia, and subsequent bacterial infections, promotes vaccination uptake in both individuals and parents. Campaigns for public health and educational programs support immunization as a preventative approach.
• Increasing Vaccination Coverage: Market expansion is fueled by initiatives to increase vaccination rates, especially in underprivileged groups and areas with high rates of disease. Varicella virus vaccinations are more widely available and disease transmission is decreased through targeted vaccination campaigns, school-based immunization programs, and outreach activities.
• Economic Benefits of Vaccination: By lowering healthcare expenses related to disease treatment, hospitalization, and lost productivity due to illness, vaccination against varicella and herpes zoster delivers financial benefits. Studies on health economics show that immunization against the varicella virus is affordable, which encourages market expansion.
• Growing Healthcare Expenditure: As a result of variables including population expansion, aging populations, and the development of a more advanced healthcare infrastructure, there is a greater ability to invest in preventative healthcare measures like vaccinations. Increased investment in healthcare facilitates the growth of the varicella virus vaccine market.
• Global Vaccine-Preventable Disease activities: Global activities to prevent and control vaccine-preventable diseases, such as varicella, have a positive impact on market growth. Governments, international organizations, and vaccine producers work together to make varicella virus vaccinations more accessible in high-risk areas.

Global Varicella Virus Vaccine Market Restraints

Several factors can act as restraints or challenges for the Varicella Virus Vaccine Market. These may include:

• Limited Vaccination Coverage: Although vaccinations against varicella virus are available, rates of vaccination may fluctuate throughout populations and geographical areas. Uptake and coverage rates can be hampered by elements including vaccine reluctance, false information, and a lack of understanding of the significance of immunization.
• Regulatory Difficulties: Getting regulatory clearance for vaccinations against the varicella virus can be difficult and time-consuming. The expense and time required for vaccine research and commercialization may increase due to regulatory requirements such as clinical trials, post-marketing surveillance, and safety and efficacy assessments.
• Problems with Vaccine Distribution and Supply: It can be difficult to guarantee a sufficient and steady supply of varicella virus vaccinations to satisfy demand. The availability of vaccines may be impacted by manufacturing setbacks, supply chain disruptions, and distribution issues, especially in areas with inadequate healthcare resources and infrastructure.
• High Manufacturing Costs: Specialized manufacturing techniques and strict quality control methods are required in the production of varicella virus vaccines. The price and accessibility of vaccines can be impacted by high manufacturing costs, which include investments in facilities, equipment, and raw materials, especially in low- and middle-income nations.
• Cold Chain Requirements: To preserve potency and efficacy, varicella virus vaccinations, like many others, need to be strictly temperature-controlled throughout the cold chain. Cold chain logistics, which include handling, storage, and transportation, can present logistical difficulties and raise expenses for producers and distributors of vaccines.
• Competition from Alternative vaccinations: Immunization plans for preventing varicella (chickenpox) and alternative vaccinations provide a threat to varicella viral vaccines. The market demand for stand-alone varicella vaccinations may be impacted by certain nations' decision to use combination vaccines, which provide protection against several diseases.
• Disease Epidemiology and Demographic Trends: Varicella (chickenpox) is a disease whose epidemiology can alter over time and between geographical areas due to a variety of factors, including population density, vaccine coverage rates, and demographic shifts. Varicella epidemiological shifts or declining disease prevalence might affect market dynamics and vaccination demand.
• Vaccine Safety Concerns: Adverse occurrences or safety concerns related to varicella virus vaccines have the potential to erode public confidence in immunization campaigns. Maintaining vaccination acceptance and uptake requires addressing safety concerns, carrying out stringent post-marketing surveillance, and being open and honest with healthcare practitioners and the general public.
• Healthcare Budget Restraints: Government financing and investment in varicella vaccination programs may be restricted due to competing healthcare objectives and budgetary restrictions. Inadequate financial resources may prevent underprivileged populations from getting vaccines and impede efforts to increase immunization rates.
• Pandemics and infectious disease outbreaks are examples of global health emergencies that might impede regular immunization programs and take funds away from efforts to vaccinate against varicella. Public health emergencies may also lead to a boost in vaccination demand, further taxing healthcare systems and vaccine supply networks.

Global Varicella Virus Vaccine Market Segmentation Analysis

The Global Varicella Virus Vaccine Market is Segmented on the basis of Vaccine Type, Application, End-User, and Geography.

Varicella Virus Vaccine Market, By Vaccine Type

• Monovalent Varicella Vaccine: A vaccine containing only the varicella zoster virus antigen, used for the prevention of varicella (chickenpox) infection.
• Combination Vaccines: Varicella vaccine may also be included in combination vaccines along with other antigens, such as measles, mumps, and rubella (MMR vaccine) or measles, mumps, rubella, and varicella (MMRV vaccine).

Varicella Virus Vaccine Market, By, Application

• Routine Immunization: Varicella vaccine is administered as part of routine childhood immunization schedules in many countries to prevent chickenpox.
• Outbreak Control: Varicella vaccine may be used in outbreak situations to control the spread of chickenpox in schools, communities, or other settings.
• Travel Vaccination: Varicella vaccine may be recommended for individuals traveling to regions where chickenpox is more common or for specific travel-related purposes.
• Post-Exposure Prophylaxis: Varicella vaccine may be given to susceptible individuals after exposure to varicella-zoster virus (VZV) to prevent or attenuate infection.

Varicella Virus Vaccine Market, By End-User

• Pediatric Clinics: Healthcare facilities specializing in pediatric care where varicella vaccine is administered to children as part of routine immunization schedules.
• Family Medicine Clinics: Healthcare facilities offering primary care services where varicella vaccine may be administered to children and adults.
• Public Health Departments: Government agencies responsible for public health initiatives, including vaccination programs and outbreak response.
• Travel Clinics: Specialty clinics providing travel-related health services where varicella vaccine may be offered to travelers.
• Pharmacies: Retail pharmacies or community health centers where varicella vaccine may be available for administration.

Varicella Virus Vaccine Market, By Geography

• North America: Includes the United States and Canada, where varicella vaccine is routinely administered as part of childhood immunization schedules.
• Europe: Includes countries such as Germany, the UK, France, Italy, and Spain, where varicella vaccine availability and usage may vary.
• Asia-Pacific: Includes countries such as China, Japan, India, and Australia, where varicella vaccine may be recommended for specific populations or in certain regions.
• Latin America: Includes countries such as Brazil, Mexico, and Argentina, where varicella vaccine may be included in national immunization programs.
• Middle East and Africa: Regions where varicella vaccine availability and usage may be limited or targeted towards specific populations.

Key Players

The "Global Varicella Virus Vaccine Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as Bio-Med Pvt. Limited, Changchun BCHT Biotechnology Co. Ltd., Emcure Pharmaceuticals Limited, GlaxoSmithKline plc, Green Cross Holdings (GC Pharma), Merck & Co. Inc., Mitsubishi Chemical Holdings Corporation, Novo Medi Sciences Pvt. Ltd., Sanofi, and Takeda Pharmaceutical Company Limited. The competitive landscape section includes key development strategies, market share analysis, and market positioning analysis of the aforementioned competitors internationally. Additionally, our market analysis includes a part devoted explicitly to these leading players. Our experts give an overview of each player's financial statements, product benchmarking, and SWOT analysis.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL VARICELLA VIRUS VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL VARICELLA VIRUS VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL VARICELLA VIRUS VACCINE MARKET, BY VACCINE

• 5.1 Overview
• 5.2 Monovalent Varicella Vaccine
• 5.3 Combination Varicella Vaccine

6 GLOBAL VARICELLA VIRUS VACCINE MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Chickenpox immunization
• 6.3 Herpes Zoster Immunization
• 6.4 Mumps
• 6.5 Measles
• 6.6 Rubella
• 6.7 Varicella (MMRV) Immunization

7 GLOBAL VARICELLA VIRUS VACCINE MARKET, BY PROVIDER

• 7.1 Overview
• 7.2 Public Provider
• 7.3 Private Provider

8 GLOBAL VARICELLA VIRUS VACCINE MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL VARICELLA VIRUS VACCINE MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Bio-Med Pvt. Limited
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Changchun BCHT Biotechnology Co. Ltd.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Emcure Pharmaceuticals Limited
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 GlaxoSmithKline plc
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Green Cross Holdings (GC Pharma)
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Merck & Co. Inc.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Development
• 10.7 Mitsubishi Chemical Holdings Corporation
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Novo Medi Sciences Pvt. Ltd.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Sanofi
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Development
• 10.10 Takeda Pharmaceutical Company Limited
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Development

11 Appendix

• 11.1 Related Research